• 3D Organoid-CAF Co-culture Reveals Stroma-Driven Chemoresist

  2026-05-15

  Schuth et al. establish a patient-specific 3D co-culture model of pancreatic cancer organoids and matched fibroblasts, uncovering key stromal mechanisms underlying chemoresistance. Their approach integrates single-cell transcriptomics and functional assays, providing a more faithful platform for evaluating drug response and tumor-stroma interactions in pancreatic ductal adenocarcinoma.

• Phosphatase Inhibitor Cocktail 1 (100X in DMSO): Technical G

  2026-05-14

  Phosphatase Inhibitor Cocktail 1 (100X in DMSO) addresses the challenge of protein dephosphorylation during sample preparation by inhibiting alkaline and serine/threonine phosphatases. It is optimized for preserving phosphorylation states in animal tissue and cell lysates for downstream applications such as Western blotting and phosphoproteomic analysis. This reagent is not intended for diagnostic or therapeutic use, and its efficacy is limited to workflows requiring endogenous phosphatase inhibition.

• Translational Immunofluorescence: Mechanistic Precision with

  2026-05-14

  This thought-leadership article explores how the HyperFluor™ 594 Goat Anti-Rabbit IgG (H+L) Antibody advances translational research through mechanistic rigor, robust protocol guidance, and strategic integration in complex biological models. Drawing on recent advances in biomimetic drug delivery for neuroblastoma and validated immunodetection workflows, we contextualize the antibody’s role in bridging mechanistic insights and clinical translation, with actionable recommendations for researchers.

• Phenytoin in Sodium Channel Modulation: Advanced CNS Assays

  2026-05-13

  Leverage Phenytoin (5,5-diphenylimidazolidine-2,4-dione) to dissect voltage-gated sodium channel pathways and myelin dynamics in neurological disease models. Drawing from recent breakthroughs in myelin remodeling, this guide outlines robust workflows, troubleshooting strategies, and protocol innovations for precise electrophysiology and neuroprotection research.

• Exo1: Mechanism and Benchmarks of a Preclinical Exocytic Pat

  2026-05-13

  Exo1 (methyl 2-(4-fluorobenzamido)benzoate) is a selective chemical inhibitor of the exocytic pathway with a unique mechanism that acutely disrupts Golgi-to-ER membrane trafficking. It enables high-specificity studies of exocytosis and ARF1 dynamics, and is characterized by its distinct action from Brefeldin A. Exo1 provides a precise tool for preclinical research into membrane trafficking and tumor extracellular vesicle biology.

• HSC70-Mediated Viral Entry: Insights from TGEV M Protein Int

  2026-05-12

  This article examines the discovery that the TGEV coronavirus membrane (M) protein engages HSC70 to facilitate viral internalization via clathrin-mediated endocytosis. The study establishes a novel role for HSC70 ATPase activity in viral entry, illuminating new host-directed antiviral strategies and providing a mechanistic bridge to Hsp70 inhibition workflows.

• Structural Basis of Primidone-Mediated TRPM3 Inhibition

  2026-05-12

  Yin et al. provide the first cryo-EM structures of TRPM3 bound to neurosteroids, synthetic agonist, and the anticonvulsant Primidone (Mysoline), revealing molecular mechanisms underlying TRPM3 regulation. These insights clarify how TRPM3 inhibition may be leveraged in neurodevelopmental and pain disorders, paving the way for rational drug design and translational research.

• Lyso-Tracker Red: Advancing Lysosome Dynamics in Tumor Immun

  2026-05-11

  Explore how Lyso-Tracker Red enables high-specificity lysosome labeling in live cells, unlocking deeper insights into lysosomal function in tumor immunology. This article uniquely bridges probe biophysics with emerging applications in immunotherapy research.

• OTUD3 Stabilizes SLC7A11 to Drive Sunitinib Resistance in cc

  2026-05-11

  This study elucidates how OTUD3 overexpression in clear cell renal cell carcinoma (ccRCC) promotes sunitinib resistance by stabilizing SLC7A11, thereby inhibiting ferroptosis. The findings highlight a mechanistic link between deubiquitination, cystine transport, and lipid peroxidation suppression, offering new therapeutic targets for overcoming drug resistance.

• ApexPrep DNA Plasmid Miniprep Kit: High-Purity Plasmid DNA W

  2026-05-10

  Unlock rapid, high-yield molecular biology grade plasmid DNA with the ApexPrep DNA Plasmid Miniprep Kit—engineered for both high- and low-copy vectors. This kit streamlines experimental workflows, supports demanding applications like AML research, and offers actionable troubleshooting for robust and reproducible results.

• Dual-Action p38α Inhibitors: Structural Mechanisms and Resea

  2026-05-09

  This study reveals that certain kinase inhibitors, including those targeting p38α MAP kinase, not only block kinase activity but also promote phosphatase-mediated dephosphorylation by altering the activation loop conformation. These findings introduce a dual-action strategy to improve specificity and efficacy in modulating the p38 MAPK signaling pathway, offering new directions for anti-inflammatory and cancer research.

• BMN 673 (Talazoparib): Precision Tools for DNA Repair Resear

  2026-05-09

  BMN 673 (Talazoparib) sets a new standard for selective PARP1/2 inhibition, delivering unmatched potency and DNA repair pathway selectivity in homologous recombination deficient models. This guide translates recent mechanistic insights and experimental best practices into actionable protocols, workflow enhancements, and troubleshooting strategies for bench scientists tackling DNA repair deficiency targeting.

• Guanabenz Acetate: Precision α2-Adrenergic Receptor Agonist

  2026-05-08

  Guanabenz Acetate redefines experimental clarity for decoding α2-adrenergic receptor subtypes in GPCR signaling and neuroimmunology. This guide provides applied protocols, troubleshooting intelligence, and translational insights—from stress granule manipulation to immune pathway modulation—leveraging the latest SARS-CoV-2 mechanistic breakthroughs.

• Novel Allosteric PDK4 Inhibitors for Metabolic Disease Thera

  2026-05-07

  This study introduces a new series of allosteric pyruvate dehydrogenase kinase 4 (PDK4) inhibitors, featuring compound 8c with strong in vitro potency and favorable pharmacokinetics. The results support PDK4 targeting as a promising approach for treating metabolic, allergic, and proliferative diseases.

• GI 254023X: Reliable ADAM10 Inhibition for Sensitive Assays

  2026-05-07

  This article explores the laboratory applications of GI 254023X (SKU A4436), a nanomolar-potency ADAM10 inhibitor, by addressing real-world scenarios in cell viability, apoptosis, and endothelial barrier research. Through data-driven Q&A, we highlight how GI 254023X from APExBIO supports reproducibility, selectivity, and workflow safety in advanced biomedical experiments.

449 records 18/30 page Previous Next First page 上5页 1617181920 下5页 Last page